Investors who bought shares of China Shineway Pharmaceutical Group (HKG: 2877) a year ago are now up 54%



If you want to accumulate wealth in the stock market, you can do so by purchasing an index fund. But if you choose the right individual stocks, you could earn more than that. Namely, the China Shineway Pharmaceutical Group Limited (HKG: 2877) The stock price is 54% higher than it was a year ago, much better than the market return of around 20% (excluding dividends) over the same period. If he can maintain this outperformance over the long term, investors will do very well! When you zoom out, the stock is actually down 40% in the last three years.

Check out our latest review for China Shineway Pharmaceutical Group

It is undeniable that markets are sometimes efficient, but prices do not always reflect the underlying performance of companies. By comparing earnings per share (EPS) and changes in the share price over time, we can get a sense of how investors’ attitudes towards a company have changed over time.

In the past year, China Shineway Pharmaceutical Group has seen its earnings per share drop by 39%.

Given the rise in the share price, we doubt the market will measure EPS progress. Therefore, it seems likely that investors will place more importance on measures other than BPA, for the time being.

We haven’t seen China Shineway Pharmaceutical Group increase dividend payouts yet, so the yield likely hasn’t helped push the stock up. The slightly lower turnover is not particularly impressive at first glance, which therefore does not explain the rise in the share price.

You can see how income and income have changed over time in the image below (click on the graph to see the exact values).

SEHK: 2877 Revenue and Revenue Growth July 3, 2021

If you are planning to buy or sell shares of China Shineway Pharmaceutical Group, you should check this out FREE detailed report on its balance sheet.

What about dividends?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. While the share price return reflects only the change in the share price, the TSR includes the value of dividends (assuming they have been reinvested) and the benefit of any capital increase or spin- off updated. So, for companies that pay a generous dividend, the TSR is often much higher than the return on the share price. We note that for China Shineway Pharmaceutical Group, the TSR in the past year was 63%, which is better than the share price performance mentioned above. The dividends paid by the company thus boosted the total shareholder return.

A different perspective

It is nice to see that the shareholders of China Shineway Pharmaceutical Group have received a total shareholder return of 63% in the past year. And that includes the dividend. As the 1-year TSR is better than the 5-year TSR (the latter standing at 5% per year), it seems that the stock’s performance has improved in recent times. At the best of times, this can portend real business momentum, meaning that now may be a good time to dig deep. I find it very interesting to look at the long-term share price as an indicator of company performance. But to really understand better, we have to take other information into account as well. Nevertheless, be aware that China Shineway Pharmaceutical Group shows 4 warning signs in our investment analysis , you must know…

We will like China Shineway Pharmaceutical Group better if we see big insider buying. In the meantime, watch this free list of growing companies with significant and recent insider buying.

Please note that the market returns quoted in this article reflect the market-weighted average returns of stocks currently traded on the Hong Kong stock exchanges.

When trading stocks or any other investment, use the platform considered by many to be the gateway for professionals to the global market, Interactive Brokers. You get the cheapest * trading on stocks, options, futures, forex, bonds and funds from around the world from one integrated account.

This Simply Wall St article is general in nature. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative material. Simply Wall St has no position in the mentioned stocks.
*Interactive Brokers Ranked Least Expensive Broker By Online Annual Review 2020

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)



Leave A Reply